Showing 2623 results
- https://www.novartis.com/news/media-releases/novartis-erweitert-partnerschaft-mit-medicines-malaria-venture-zur-entwicklung-von-malariamedikamenten-der-nachsten-generationNovartis wird die Entwicklung des Malariapräparats KAF156 mit wissenschaftlicher und finanzieller Unterstützung von Medicines for Malaria Venture in Zusammenarbeit mit der Bill & Melinda Gates…
- https://www.novartis.com/news/media-releases/novartis-etend-son-partenariat-avec-medicines-malaria-venture-pour-developper-la-prochaine-generation-de-traitement-antipaludeenNovartis dirigera le développement de la molécule antipaludique KAF156 avec le soutien scientifique et financier de Medicines for Malaria Venture et en collaboration avec la Fondation Bill &…
- https://www.novartis.com/news/media-releases/novartis-highlights-long-term-safety-data-revolade-adults-chronic-immune-thrombocytopenia-rare-blood-disorderEXTEND study provides long-term safety data for Revolade that are consistent with the findings from the pivotal Phase III RAISE study[1,2] Immune thrombocytopenia (ITP) is a rare and potentially…
- https://www.novartis.com/news/media-releases/novartis-presents-data-showing-jakavi-superior-best-available-therapy-patients-less-advanced-polycythemia-vera-pvThree times as many patients with inadequately controlled PV without enlarged spleen had hematocrit control without phlebotomy on Jakavi® (ruxolitinib) vs BAT[1] RESPONSE-2 complements data…
- https://www.novartis.com/news/media-releases/new-data-demonstrates-sandoz-etanercept-and-rituximab-biosimilar-candidates-bioequivalent-originator-productsSandoz' biosimilar etanercept candidate shows pharmacokinetic (PK) bioequivalence with no clinically meaningful differences in safety, tolerability and immunogenicity to the originator.[1] …
- https://www.novartis.com/news/media-releases/sandoz-announces-exclusive-deal-commercialize-biosimilar-ustekinumab-further-reinforcing-growing-pipeline-and-immunology-patient-offeringAgreement with Samsung Bioepis gives Sandoz exclusive commercialization rights to biosimilar SB17 ustekinumab in Europe and North AmericaUstekinumab is a fully human monoclonal antibody to…
- https://www.novartis.com/news/media-releases/novartis-announces-amg-334-significantly-reduces-patients-monthly-migraine-days-phase-ii-study-chronic-migraine-preventionPhase II 20120295 study of AMG 334 met primary endpoint, confirming efficacy and safety in patients with chronic migraine over 12 weeks of treatment Migraine is a leading cause of disability,…
- https://www.novartis.com/news/novartis-giving-volunteering-wins-accps-2023-corporate-social-impact-team-year-award
- https://www.novartis.com/about/people-and-culture/giving-volunteering/non-profit-partnering-positive-sustainable-social-change
- https://www.novartis.com/news/gt005-ppy988-development-program-geographic-atrophy
Pagination
- ‹ Previous page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- …
- 263
- › Next page